Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis

被引：0
|
作者：
Earla, Jagadeswara Rao [1 ]
Hutton, George Joseph [2 ]
Thornton, J. Douglas [1 ]
Chen, Hua [1 ]
Johnson, Michael L. [1 ]
Aparasu, Rajender R. [1 ]
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3956
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [31] Multiple sclerosis: Fingolimod is an effective oral treatment for MS
    Jones N.
    Nature Reviews Neurology, 2010, 6 (3) : 121 - 121
  • [32] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Stefan Braune
    M. Lang
    A. Bergmann
    Journal of Neurology, 2016, 263 : 327 - 333
  • [33] Fingolimod: a novel oral immunomodulatory treatment for multiple sclerosis
    Javed, Adil
    Soliven, Betty
    FUTURE NEUROLOGY, 2011, 6 (03) : 315 - 325
  • [34] Initiating oral fingolimod treatment in patients with multiple sclerosis
    Singer, Barry A.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2013, 6 (04) : 269 - 275
  • [35] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Braune, Stefan
    Lang, M.
    Bergmann, A.
    JOURNAL OF NEUROLOGY, 2016, 263 (02) : 327 - 333
  • [36] Disease modifying treatment in multiple sclerosis
    Fuller, GN
    Bone, I
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 : II20 - II21
  • [37] Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis A Registry-Based Study
    Spelman, Tim
    Simoneau, Gabrielle
    Hyde, Robert
    Kuhelj, Robert
    Alroughani, Raed
    Ozakbas, Serkan
    Karabudak, Rana
    Yamout, Bassem I.
    Khoury, Samia J.
    Terzi, Murat
    Boz, Cavit
    Horakova, Dana
    Kubala Havrdova, Eva
    Weinstock-Guttman, Bianca
    Patti, Francesco
    Altintas, Ayse
    Mrabet, Saloua
    Gouider, Riadh
    Inshasi, Jihad
    Shaygannejad, Vahid
    Eichau, Sara
    Ward, W. Luke
    Butzkueven, Helmut
    NEUROLOGY, 2024, 102 (07) : e208114
  • [38] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis (vol 43, pg 473, 2023)
    Earla, J. R.
    Li, J.
    Hutton, G. J.
    Johnson, M. L.
    Aparasu, R. R.
    PHARMACOTHERAPY, 2024, 44 (09): : 753 - 753
  • [39] Real-world Effectiveness Of Initial Treatment With Newer Versus Injectable Disease-modifying Therapies In Pediatric Multiple Sclerosis
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Anita, B.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M. S.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Ness, J.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Tillema, J.
    Waltz, M.
    Casper, T.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 47
  • [40] Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2020, 94 (15)
12345